Indonesian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
chloroquine/muntah
Tautan disimpan ke clipboard
Halaman 1 dari 18 hasil
Efficacy of Sunlight Activated Synthetic Porphyrin in COVID-19 Infected Patients
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
Efficacy of Sunlight Activated Synthetic Porphyrin in COVID-19 Infected Patients (SnPPIX)
Official Title: Efficacy of Based MRI Contrast Media Against Covid-19
_____________________________________________________________________________________________
Hydroxychloroquine and Nitazoxanide Combination Therapy for COVID-19
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
Selected Drugs
Hydroxychloroquine (an analog of chloroquine) has been demonstrated to have an anti-SARS-CoV activity in vitro. Hydroxychloroquine clinical safety profile is better than that of chloroquine (during long-term use) and allows higher daily dose and has fewer concerns about drug-drug
Chloroquine Phosphate Against Infection by the Novel Coronavirus SARS-CoV-2 (COVID-19): The HOPE Open-Label, Non Randomized Clinical Trial
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
Humanity has been experiencing a new pandemic of the SARS Coronavirus-19 virus (SARS-CoV-2) since December 2019, causing the disease known as COVID-19. As of March 23, 2020, there have been 382,341 documented episodes of infection worldwide, of which 16,567 have died. An important limitation in the
Hydroxychloroquine for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
Inclusion criteria:
- Adult patients (>18 years)
- Confirmed COVID-19 infection by real-time PCR from a respiratory or other body sample within 48 hours of testing.
- Mild to moderate infection or asymptomatic patients with comorbidities: Symptomatic patients with fever >37.9ºC or cough or dyspnea
Determining the Impact of Scaling up Mass Testing, Treatment and Tracking on Malaria Prevalence in Ghana
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
Background Malaria continues to pose a serious burden to the local populations in sub-Sahara Africa. Several efforts have been made to scale up interventions that work such as preventing man-vector contact, intermittent preventive therapy, seasonal malaria chemoprophylaxis as well as TTT for febrile
TES Artemether-lumefantrine for Pf and Chloroquine (CQ) for Pv
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
1. BACKGROUND In 2002, the Philippines changed its antimalarial drug policy to the combination treatment, CQ+ Sulphadoxine-pyrimethamine (SP) as 1st-line treatment and artemether-lumefantrine as 2nd-line treatment. The Department of Health (DOH) prescribed the use of artemether-lumefantrine (AL)
Impact of Scaling up Mass Testing, Treatment and Tracking on Malaria Prevalence Among Children
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
Introduction/Rationale
The World Health Organization (WHO) in 2010 reported that malaria was endemic in 96 countries reflecting an improvement of the situation of 2005 where it was endemic in 106 countries. Malaria morbidity and mortality remain a serious problem in sub Saharan Africa especially in
Pre-delivery Administration of Azithromycin to Prevent Neonatal Sepsis & Death
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
other data elements, such as eligibility criteria or outcome measures. (Limit: 32,000 characters) Project title: Pre-delivery administration of azithromycin to prevent neonatal sepsis and death: a phase III double-blind randomized clinical trial Acronym: PregnAnZI-2
LIST OF INVESTIGATORS
Chief
Antimalaria Drugs Susceptibility Testing for an Effective Management of Infected Patients in Sub-Sahara Africa
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
Malaria incidence has increased two- to three-folds over the past four decades, and nearly half the world's population now lives in regions endemic for malaria: In Asia, Africa, and South America. A global annual estimate of 300-500 clinical cases of malaria and mortality in the range of 1-2 million
G6PD Assessment Before Primaquine for Radical Treatment of Vivax Malaria
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
1. Screening All patients registering for outpatient services in the outpatient department will undergo routine investigation. When malaria is suspected, a thick and thin blood smear will be obtained for microscopic diagnosis of Plasmodium vivax or a malaria RDT undertaken. After the diagnosis is
Efficacy of Chloroquine (CQ) Alone Compared to Concomitant CQ and Primaquine for Plasmodium Vivax Infection
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
1. OBJECTIVE- To assess the efficacy of co-administered chloroquine+primaquine (CQ+PQ) vs.CQ alone (PQ being postponed up to day 28 of CQ therapy) as a schizontocidal therapy (28-day follow-up) and as radical cure among uncomplicated P. vivax malaria (6-month follow-up). Specifically:
- To measure
Efficacy of Artesunate-amodiaquine and Artemether-lumefantrine for Uncomplicated Malaria in South Kivu, DR Congo
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
3.1 STUDY DESIGN Children with uncomplicated malaria meeting the inclusion criteria will be enrolled (after their parent/caretaker has given informed consent), treated on site with the drugs under evaluation and followed-up for a period of 42 days. Drugs will be given under direct supervision,
Evaluating the Efficacy of Chloroquine for the Treatment of Plasmodium Vivax Infections in Central Vietnam
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
3.1 Study Design This study is designed as a 42-day drug efficacy study to evaluate clinical and parasitological responses after treatment of P.vivax malaria infections. Symptomatic patients with P. vivax mono-infections, meeting the study criteria, will be enrolled into the study, and treated with
Improving Anti-malarial Treatment Options in Guinea-Bissau - Part A
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
Background Plasmodium falciparum causes malaria and approximately 665 000 deaths each year. Previously chloroquine (CQ) and sulphadoxine-pyrimethamine were the principle drugs for the treatment of malaria. Due to widespread resistance to these drugs1, the World Health Organization recommends that P.
Ph 2B/3 Tafenoquine (TFQ) Study in Prevention of Vivax Relapse
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
Plasmodium vivax represents 50-80% of all malarial cases in Latin America and South East Asia. It is able to establish a dormant liver stage called the hypnozoite. Hypnozoite activation after initial infection can cause a relapse. Currently the only widely available drug is primaquine which requires
Database tanaman obat terlengkap yang didukung oleh sains
- Bekerja dalam 55 bahasa
- Pengobatan herbal didukung oleh sains
- Pengenalan herbal melalui gambar
- Peta GPS interaktif - beri tag herba di lokasi (segera hadir)
- Baca publikasi ilmiah yang terkait dengan pencarian Anda
- Cari tanaman obat berdasarkan efeknya
- Atur minat Anda dan ikuti perkembangan berita, uji klinis, dan paten
Ketikkan gejala atau penyakit dan baca tentang jamu yang mungkin membantu, ketik jamu dan lihat penyakit dan gejala yang digunakan untuk melawannya.
* Semua informasi didasarkan pada penelitian ilmiah yang dipublikasikan
